

# Juan-Manuel Sancho

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1037826/juan-manuel-sancho-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

141  
papers

1,436  
citations

20  
h-index

34  
g-index

167  
ext. papers

1,763  
ext. citations

3  
avg, IF

3.99  
L-index

#	Paper	IF	Citations
141	Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1462-9	2.2	163
140	Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. <i>Lancet Haematology</i> , <b>2020</b> , 7, e511-e522	14.6	97
139	Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia. <i>Leukemia and Lymphoma</i> , <b>2008</b> , 49, 1752-61	1.9	81
138	Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. <i>Lancet Haematology</i> , <b>2017</b> , 4, e362-e373	14.6	58
137	First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial. <i>Lancet Haematology</i> , <b>2014</b> , 1, e104-11	14.6	55
136	Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma. <i>Haematologica</i> , <b>2014</b> , 99, 1228-35	6.6	52
135	Outcome and prognostic factors in patients with hematologic malignancies admitted to the intensive care unit: a single-center experience. <i>International Journal of Hematology</i> , <b>2007</b> , 85, 195-202	2.3	50
134	Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>European Journal of Haematology</i> , <b>2007</b> , 78, 102-10	3.8	46
133	Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma. <i>Blood</i> , <b>2017</b> , 130, 1772-1774	2.2	44
132	Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis. <i>Cancer</i> , <b>2006</b> , 106, 2540-6	6.4	43
131	Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era. <i>European Journal of Haematology</i> , <b>2010</b> , 85, 321-8	3.8	42
130	Predictive factors for poor peripheral blood stem cell mobilization and peak CD34(+) cell count to guide pre-emptive or immediate rescue mobilization. <i>Cytotherapy</i> , <b>2012</b> , 14, 823-9	4.8	39
129	Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial. <i>Lancet Haematology</i> , <b>2018</b> , 5, e543-e553	14.6	38
128	Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma. <i>Cancer</i> , <b>2009</b> , 115, 1892-8	6.4	33
127	Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier. <i>Blood</i> , <b>2020</b> , 135, 996-1007	2.2	32
126	Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO). <i>Haematologica</i> , <b>2017</b> , 102, 235-245	6.6	29
125	Delayed haemolytic transfusion reaction due to anti-M antibody. <i>British Journal of Haematology</i> , <b>1998</b> , 103, 268-9	4.5	24

124	HIV-infection impact on clinical-biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era. <i>Aids</i> , <b>2015</b> , 29, 811-8	3.5	23
123	MYC protein expression is associated with poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system. <i>Apmis</i> , <b>2015</b> , 123, 596-603	3.4	23
122	Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome. <i>Blood</i> , <b>2014</b> , 123, 1864-9	2.2	23
121	Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high-dose melphalan for autologous stem cell transplantation for lymphoma and myeloma. <i>European Journal of Haematology</i> , <b>2014</b> , 93, 487-91	3.8	18
120	Current prognostic and predictive factors in follicular lymphoma. <i>Annals of Hematology</i> , <b>2018</b> , 97, 209-227		17
119	Translocation (3;8)(q27;q24) in two cases of triple hit lymphoma. <i>Cancer Genetics and Cytogenetics</i> , <b>2010</b> , 203, 328-32		17
118	A Randomized Phase II Study Comparing Consolidation With a Single Dose Of 90y Ibritumomab Tiuxetan (Zevalin®) (Z) Vs. Maintenance With Rituximab (R) For Two Years In Patients With Newly Diagnosed Follicular Lymphoma (FL) Responding To R-CHOP. Preliminary Results At 36 Months From Randomization. <i>Blood</i> , <b>2013</b> , 122, 369-369	2.2	17
117	Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome. <i>Hematological Oncology</i> , <b>2017</b> , 35, 520-527	1.3	15
116	Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population. <i>British Journal of Haematology</i> , <b>2019</b> , 185, 480-491	4.5	14
115	Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL). <i>Blood</i> , <b>2019</b> , 134, 4089-4089	2.2	13
114	The long term follow-up of early stage follicular lymphoma treated with radiotherapy, chemotherapy or combined modality treatment. <i>Leukemia Research</i> , <b>2015</b> , 39, 853-8	2.7	12
113	Results of compassionate therapy with intrathecal depot liposomal cytarabine in acute myeloid leukemia meningeosis. <i>International Journal of Hematology</i> , <b>2007</b> , 86, 33-6	2.3	12
112	Contempo: Preliminary Results in First-Line Treatment of Follicular Lymphoma with the Oral Dual PI3K- $\gamma$ Inhibitor, Duvelisib, in Combination with Rituximab or Obinutuzumab. <i>Blood</i> , <b>2016</b> , 128, 2979-2979	2.2	11
111	First European Chemotherapy Schedule for Elderly Patients with Acute Lymphoblastic Leukemia: Promising Remission Rate and Feasible Moderate Dose Intensity Consolidation. <i>Blood</i> , <b>2008</b> , 112, 304-304	2.2	10
110	Pharmacokinetic and Safety of CT-P10, a Biosimilar Candidate to the Rituximab Reference Product, in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma (AFL). <i>Blood</i> , <b>2016</b> , 128, 1807-1807	2.3	10
109	Plasma Epstein-Barr Virus Load as an Early Biomarker and Prognostic Factor of Human Immunodeficiency Virus-related Lymphomas. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 68, 834-843	11.6	9
108	Mobilization and engraftment of peripheral blood stem cells in healthy related donors >55 years old. <i>Cytotherapy</i> , <b>2014</b> , 16, 406-11	4.8	9
107	Clinicopathologic features and prognostic significance of CD30 expression in diffuse large B-cell lymphoma (DLBCL): results in a homogeneous series from a single institution. <i>Biomarkers</i> , <b>2020</b> , 25, 69-75	2.6	9

106	Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma. <i>Cancer Medicine</i> , <b>2021</b> , 10, 3214-3223	4.8	9
105	Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain. <i>Leukemia Research</i> , <b>2012</b> , 36, 709-14	2.7	8
104	Plerixafor plus G-CSF in combination with chemotherapy for stem cell mobilization in a pediatric patient with Ewing's sarcoma. <i>Journal of Clinical Apheresis</i> , <b>2012</b> , 27, 260-2	3.2	8
103	Prospective study on the practice of central nervous system prophylaxis and treatment in non-Hodgkin's lymphoma in Spain. <i>Medicina Clínica</i> , <b>2008</b> , 131, 441-6	1	8
102	Final Results of a Multicenter Phase II Trial with Bendamustine and Rituximab As First Line Treatment for Patients with MALT Lymphoma (MALT-200801). <i>Blood</i> , <b>2012</b> , 120, 3691-3691	2.2	7
101	Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial. <i>Annals of Hematology</i> , <b>2017</b> , 96, 639-646	3	6
100	Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPi study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2015</b> , 15, 398-403	2	6
99	Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma. <i>Oncotarget</i> , <b>2018</b> , 9, 32383-32399	3.3	6
98	Treatment of localized-stage follicular lymphoma. <i>European Journal of Haematology</i> , <b>2018</b> , 101, 245	3.8	6
97	Incidence, predictive factors, management, and survival impact of atrial fibrillation in non-Hodgkin lymphoma. <i>Annals of Hematology</i> , <b>2018</b> , 97, 1633-1640	3	5
96	Title:Dose-Adjusted EPOCH Plus Rituximab (DA-EPOCH-R) in Untreated Patients with Poor Risk Large B-Cell Lymphoma. A Phase 2 Study Conducted by the Spanish PETHEMA Group.. <i>Blood</i> , <b>2009</b> , 114, 2701-2701	2.2	5
95	Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma. <i>Annals of Hematology</i> , <b>2020</b> , 99, 2837-2846	3	5
94	R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients 60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group. <i>Cancer Medicine</i> , <b>2021</b> , 10, 1314-1326	4.8	5
93	Recent landmark studies in follicular lymphoma. <i>Blood Reviews</i> , <b>2019</b> , 35, 68-80	11.1	4
92	Real-World Evidence of Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma. <i>Blood</i> , <b>2020</b> , 136, 19-21	2.2	4
91	CC-122 Dosing on a Novel Intermittent Schedule Mitigates Neutropenia and Maintains Clinical Activity in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma. <i>Blood</i> , <b>2015</b> , 126, 1494-1494	2.2	4
90	Global Phase I/III Pharmacokinetic and Efficacy Study Comparing CT-P10, a Biosimilar Candidate to the Rituximab Reference Product in Patients with Advanced Stage Follicular Lymphoma (AFL). <i>Blood</i> , <b>2015</b> , 126, 5111-5111	2.2	4
89	Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 1087-1091	1.9	4

88	Epstein-Barr viral loads and serum free light chains levels are potential follow-up markers of HIV-related lymphomas. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 211-213	1.9	3
87	Incidence and prognostic significance of nephrotoxicity in patients receiving eshap as salvage therapy for lymphoma. <i>Leukemia Research</i> , <b>2017</b> , 58, 98-101	2.7	3
86	Flow cytometry for detection of central nervous system disease in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 2190-2	1.9	3
85	Efficacy and safety of pixantrone for the treatment of multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. <i>European Journal of Haematology</i> , <b>2020</b> , 104, 499-508	3.8	3
84	Risk of Cardioembolic Stroke in Patients With Cancer and Atrial Fibrillation. <i>American Journal of Cardiology</i> , <b>2018</b> , 121, 1656-1657	3	3
83	New drugs for follicular lymphoma. <i>Leukemia Research</i> , <b>2016</b> , 49, 38-46	2.7	3
82	Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial. <i>Cancer Medicine</i> , <b>2019</b> , 8, 6955-6966	4.8	3
81	Relapse risk after autologous stem cell transplantation in patients with lymphoma based on CD34+ cell dose. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 916-922	1.9	3
80	Open questions in watchful waiting for follicular lymphoma. <i>British Journal of Haematology</i> , <b>2017</b> , 179, 679-681	4.5	3
79	Lymphomatoid granulomatosis of central nervous system and lung driven by epstein barr virus proliferation: successful treatment with rituximab-containing chemotherapy. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , <b>2014</b> , 6, e2014017	3.2	3
78	Practice of central nervous system prophylaxis and treatment in acute leukemias in Spain. Prospective registry study. <i>Medicina Clínica</i> , <b>2008</b> , 131, 401-5	1	3
77	POLARGO: A Randomized Phase III Study Evaluating Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Had Received One or More Previous Therapies. <i>Blood</i> , <b>2019</b> , 134, 5317-5317	2.2	3
76	Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with Ibrutinib (CITADEL-205). <i>Blood</i> , <b>2020</b> , 136, 43-44	2.2	3
75	CC-122 Expands Activated and Memory CD4 and CD8 T Cells In Vivo and Induces T Cell Activation Ex Vivo in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma and Multiple Myeloma. <i>Blood</i> , <b>2015</b> , 126, 2704-2704	2.2	3
74	Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 1-13	1.9	3
73	Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study. <i>Journal of Hematology and Oncology</i> , <b>2021</b> , 14, 111	22.4	3
72	Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients. <i>Annals of Hematology</i> , <b>2021</b> , 100, 1023-1029	3	3
71	Routine surveillance imaging in follicular lymphoma. <i>Annals of Hematology</i> , <b>2018</b> , 97, 2263-2264	3	3

70	Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study. <i>Blood Advances</i> , <b>2021</b> , 5, 3354-3361	7.8	3
69	Is Longer Progression-Free Survival a Goal Worth Pursuing in Follicular Lymphoma?. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 758	2.2	2
68	Further Examining the TROG 99.03 Trial in Early-Stage Follicular Lymphoma: Cure Rate and the Role of Positron Emission Tomography. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 256-257	2.2	2
67	m7FLIPI and targeted sequencing in high-risk follicular lymphoma. <i>Hematological Oncology</i> , <b>2019</b> , 37, 564-568	1.3	2
66	A new modified prophylactic scheme against liposomal cytarabine-induced arachnoiditis in adult patients with lymphoma. <i>Leukemia and Lymphoma</i> , <b>2013</b> , 54, 892-3	1.9	2
65	Causas por las que no se realiza el trasplante de progenitores hematopoyéticos en pacientes remitidos a una unidad de trasplante. <i>Medicina Clínica</i> , <b>2003</b> , 121, 401-404	1	2
64	A case of non-lethal pulmonary air embolism after leukapheresis catheter removal. <i>Journal of Clinical Apheresis</i> , <b>2005</b> , 20, 93-4	3.2	2
63	Long-Term Efficacy and Safety Results of CT-P10 and Reference Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma: Phase III Updated Study Results with Median Follow-up of 40 Months. <i>Blood</i> , <b>2019</b> , 134, 1528-1528	2.2	2
62	Prevalence, Predictive Factors Therapy and Outcome of Patients with Follicular Lymphoma Refractory to First Line Immunochemotherapy. <i>Blood</i> , <b>2015</b> , 126, 1510-1510	2.2	2
61	Incidence, Risk Factors and Prognosis of Transformation in Follicular Lymphoma: a Multicentre Retrospective Analysis of 1763 Patients from the GELTAMO Spanish Lymphoma Cooperative Group. <i>Blood</i> , <b>2015</b> , 126, 3944-3944	2.2	2
60	Worse outcome and distinct mutational pattern in follicular lymphoma with anti-HBc positivity. <i>Blood Advances</i> , <b>2021</b> ,	7.8	2
59	Precision medicine in follicular lymphoma: Focus on predictive biomarkers. <i>Hematological Oncology</i> , <b>2020</b> , 38, 625-639	1.3	2
58	Is there a role for the international prognostic index in follicular lymphoma?. <i>Annals of Hematology</i> , <b>2018</b> , 97, 713-715	3	2
57	Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2021</b> ,	2	2
56	Pembrolizumab for refractory primary mediastinal B-cell lymphoma with central nervous system involvement. <i>Hematological Oncology</i> , <b>2021</b> , 39, 419-422	1.3	2
55	Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 2524-2531	1.9	1
54	Incidence of solid cancer in patients with follicular lymphoma. <i>Acta Oncologica</i> , <b>2019</b> , 58, 1564-1569	3.2	1
53	Systemic thrombotic thrombocytopenic purpura (TTP) following unrelated cord blood transplantation. <i>Leukemia and Lymphoma</i> , <b>2006</b> , 47, 1173-5	1.9	1

52	The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	1
51	Effect of Prior Therapy on the Efficacy and Safety of Oral Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Study. <i>Blood</i> , <b>2019</b> , 134, 5333-5333	2.2	1
50	Efficacy of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with High-Risk Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the L-Mind Study. <i>Blood</i> , <b>2020</b> , 136, 1-2	2.2	1
49	The Prognostic Significance of Complex Karyotype in Philadelphia Chromosome-Negative (Ph <sup>-</sup> ) Acute Lymphoblastic Leukemia (ALL) in Adults Is Related with Risk Group.. <i>Blood</i> , <b>2007</b> , 110, 3501-3501	2.2	1
48	Rituximab, Bendamustine, Mitoxantrone, Dexamethasone (R-BMD) in Patients with Follicular Lymphoma in Relapse or Refractory to First-Line Treatment with Immunochemotherapy. R-BMD Geltamo 08 Trial. <i>Blood</i> , <b>2012</b> , 120, 1639-1639	2.2	1
47	Lymphomas With MYC-Translocation Other Than Burkitt's Have An Aggressive Presentation and Poor Response To Immunochemotherapy: Study Of 34 Cases. <i>Blood</i> , <b>2013</b> , 122, 5083-5083	2.2	1
46	Incidence, Treatment and Prognosis of Patients with Relapsed Burkitt Lymphoma/Leukemia Treated with Specific Chemotherapy or Immunochemotherapy in Spain. <i>Blood</i> , <b>2015</b> , 126, 2723-2723	2.2	1
45	Phase 2 Randomized Trial Comparing Standard RCHOP Versus Brcap (bortezomib, rituximab, cyclophosphamide, adriamycin and prednisone) As First Line Treatment in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma (DLBCL). a Study from Spanish Group Geltamo. <i>Blood</i> , <b>2017</b> , 129, 1821-1821	2.2	1
44	R-COMP Vs. R-CHOP As First-Line Treatment for De Novo Diffuse Large B-Cell Lymphoma in Patients Older Than 60 Years: Preliminary Results from a Prospective Randomized Phase 2 Study from the Spanish Group Geltamo. <i>Blood</i> , <b>2016</b> , 128, 5387-5387	2.2	1
43	Double-blind, randomized phase 3 study to compare efficacy and safety of the biosimilar CT-P10 to rituximab combined with CVP therapy in patients with previously untreated advanced-stage follicular lymphoma.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 7532-7532	2.2	1
42	Central Nervous System (CNS) Relapse in Adult Patients with Acute Lymphoblastic Leukemia (ALL): Frequency and Prognosis in 467 Patients without Cranial Irradiation for CNS Prophylaxis.. <i>Blood</i> , <b>2005</b> , 106, 1841-1841	2.2	1
41	Rituximab and Specific Therapy for Patients with Burkitt's Leukemia and Lymphoma. Results of the BURKIMAB14 Trial from the Spanish Pethema and Geltamo Groups in 80 Patients. <i>Blood</i> , <b>2019</b> , 134, 2584-2584 <sup>1</sup>	2.2	1
40	Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab era. <i>European Journal of Haematology</i> , <b>2020</b> , 104, 400-408	3.8	1
39	Long-term outcome comparing histological grades of follicular lymphoma patients treated with immunochemotherapy as first-line therapy: A retrospective analysis from two institutions. <i>European Journal of Haematology</i> , <b>2020</b> , 104, 198-206	3.8	1
38	Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma. <i>Future Oncology</i> , <b>2021</b> , 17, 1295-1310	3.6	1
37	The lymphocyte-to-monocyte ratio in follicular lymphoma. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 2558-2561.9	1.9	1
36	Central nervous system relapse in diffuse large B cell lymphoma: Risk factors. <i>Medicina Clínica (English Edition)</i> , <b>2016</b> , 146, 74-80	0.3	1
35	Overall survival in patients with relapsed/refractory high grade B-cell lymphomas treated with gemcitabine, oxaliplatin with or without rituximab. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 3324-3326	1.9	1

34	A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma. <i>Investigational New Drugs</i> , <b>2021</b> , 39, 1028-1035	4.3	1
33	Female patients with follicular lymphoma have a better prognosis if primary remission lasts over 24 months. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 1639-1647	1.9	1
32	A randomized phase II study comparing consolidation with a single dose of Y ibritumomab tiuxetan maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 1-8	1.9	1
31	Venous thromboembolism in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with lenalidomide: a systematic review. <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 2602-2611	1.9	0
30	Long-Term Efficacy and Safety (27 months) of the Biosimilar CT-P10 in Patients with Low Tumor Burden Follicular Lymphoma. <i>Blood</i> , <b>2020</b> , 136, 27-28	2.2	0
29	Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , <b>2021</b> , 196, 589	4.5	0
28	Comparison of Efficacy and Safety of Biosimilar CT-P10 to Rituximab in Patients with Previously Untreated Low Tumor Burden Follicular Lymphoma (LTBFL): A Randomized Phase III Study. <i>Blood</i> , <b>2018</b> , 132, 1596-1596	2.2	0
27	Impact of previous admission to an intensive care unit on stem cell transplantation outcome. <i>Medicina Clínica</i> , <b>2020</b> , 155, 382-387	1	0
26	The interval between frontline treatment and the second relapse (PFS2) predicts survival from the second relapse in follicular lymphoma patients. <i>European Journal of Haematology</i> , <b>2021</b> , 106, 428-432	3.8	0
25	Similar prognosis of transformed and de novo diffuse large B-cell lymphomas in patients treated with immunochemotherapy. <i>Medicina Clínica</i> , <b>2017</b> , 148, 243-249	1	
24	Late isolated intraocular relapse of a systemic diffuse large B-cell lymphoma detected by flow cytometry. <i>Annals of Hematology</i> , <b>2017</b> , 96, 523-524	3	
23	Arterial Thromboembolism in Non-Hodgkin Lymphoma. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 258-259	15.1	
22	Second neoplasms in adult patients submitted to haematopoietic stem cell transplantation. <i>Medicina Clínica</i> , <b>2018</b> , 150, 421-427	1	
21	Mobilization of peripheral blood stem cells with plerixafor in poor mobilizer patients. <i>Medicina Clínica (English Edition)</i> , <b>2016</b> , 147, 223.e1-223.e7	0.3	
20	The persistent uncertainty of when to recommend allogeneic stem cell transplantation in follicular lymphoma. <i>Cancer</i> , <b>2018</b> , 124, 3454-3455	6.4	
19	Validation of New International Prognostic Scores, Including Baseline Peripheral Blood Variables, in Patients with Diffuse Large B-Cell Lymphoma and HIV Infection Treated with R-CHOP and Combined Antiretroviral Therapy. Retrospective Study from Spanish Lymphoma Group Geltamo. <i>Blood</i> , <b>2021</b> , 138, 2497-2497	2.2	
18	Outcome and Prognostic Factors in Patients with Hematological Malignancy That Are Admitted to the Intensive Care Unit.. <i>Blood</i> , <b>2004</b> , 104, 5285-5285	2.2	
17	The effect of duvelisib, a dual inhibitor of PI3K- $\delta$ on components of the tumor microenvironment in previously untreated follicular lymphoma.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 7579-7579	2.2	



16	Evaluation of the Effectiveness and Safety of Pixantrone for the Treatment of Multiply Relapsed or Refractory Aggressive Non Hodgkin B-Cell Lymphoma (aNHL) an Observational Multicentre Retrospective Study in a Real World Population. <i>Blood</i> , <b>2018</b> , 132, 1716-1716	2.2
15	Idelalisib for Relapsed/Refractory Follicular Lymphoma: Retrospective Study from Spanish Lymphoma Group Geltamo (GELT-IDE-2018-02). <i>Blood</i> , <b>2019</b> , 134, 5249-5249	2.2
14	Advanced Stage Hodgkin Lymphoma Has More Aggressive Characteristics but Similar Outcome in HIV-Infected Than in HIV-Negative Patients in the Combination Antiretroviral Therapy Era. <i>Blood</i> , <b>2014</b> , 124, 4435-4435	2.2
13	Epstein-Barr Virus Viral Loads and Serum Free Light Chains Levels Are Diagnostic Markers of Lymphoma in HIV-Infected Patients. <i>Blood</i> , <b>2014</b> , 124, 1697-1697	2.2
12	Validation of the NCCN-IPI for Diffuse Large B-Cell Lymphoma (DLBCL) in a Nation-Wide Spanish Series of 1885 Patients. the Geltamo-IPI Project. <i>Blood</i> , <b>2015</b> , 126, 3955-3955	2.2
11	Prognostic Factors and Treatment Results in Elderly Patients with Aggressive B-Cell Lymphoma: A Geltamo Observational Study. <i>Blood</i> , <b>2015</b> , 126, 1508-1508	2.2
10	Phase 2 Randomized Trial Comparing 6 Cycles of Standard RCHOP Chemotherapy Vs 6 Cycles of Brcap (bortezomib, rituximab, cyclophosphamide, adriamicine and prednisone) As First Line Treatment in Young Patients with Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL): Interim Analysis. <i>Blood</i> , <b>2015</b> , 126, 1514-1514	2.2
9	Gene Rearrangements and Other Molecular Features in Aggressive B-Cell Lymphomas of Patients with and without HIV-Infection. <i>Blood</i> , <b>2015</b> , 126, 3874-3874	2.2
8	Lenalidomide in Combination with R-ESHAP (LR-ESHAP) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Who Are Candidates for Autologous Stem-Cell Transplantation: A Phase 2 Study from the Spanish Group Geltamo. <i>Blood</i> , <b>2016</b> , 128, 1850-1850	2.2
7	Integrating Genomic Alterations in Diffuse Large B-Cell Lymphoma Identifies New Relevant Pathways and Potential Therapeutic Targets. <i>Blood</i> , <b>2016</b> , 128, 152-152	2.2
6	Applicability of Different Immunohistochemistry Algorithms to Assess Gene Expression Profile In Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , <b>2010</b> , 116, 4134-4134	2.2
5	Dose-Adjusted EPOCH Plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell, with Analysis of Germinal Center and Activated B-Cell Biomarkers. A Phase IV Study Conducted by the Spanish PETHEMA Group. <i>Blood</i> , <b>2011</b> , 118, 593-593	2.2
4	Differences In Clinical-Biological Features and Outcome Between Diffuse Large B-Cell Lymphomas Of HIV-Infected and Non-HIV-Infected Patients Treated With RCHOP In The CART Era. <i>Blood</i> , <b>2013</b> , 122, 1815-1815	2.2
3	The case for lymphoma-specific survival. <i>Expert Review of Hematology</i> , <b>2018</b> , 11, 263-264	2.8
2	Predictive gene-expression score for follicular lymphoma. <i>Lancet Oncology</i> , <b>2018</b> , 19, e279	2.1,7
1	Validation of the Burkitt Lymphoma International Prognostic Index in patients treated with two prospective chemoimmunotherapy trials in Spain.. <i>Leukemia and Lymphoma</i> , <b>2022</b> , 1-4	1.9